For clinicians treating chronic diseases of the skin or prescribing therapies that modify skin structure, MicroElastic's Bullseye™ instantly quantifies skin thickness and elasticity. Unlike surface palpation, Bullseye ultrasonically probes the dermis for precise, robust and repeatable measurements, previously unattainable without biopsy. We believe that Bullseye will empower clinicians to identify and connect more patients with earlier interventions, select the right therapy at the right time, and optimize long-term treatment plans for lasting skin health.

Skin elasticity is driven by the amount of collagen in the dermis. As we age, collagen degrades, and skin loses elasticity and becomes saggy. Conversely, excess buildup of collagen in skin signifies damage or disease. Unfortunately, noninvasive methods of skin assessment via pinching/suction/compression are unreliable. For accurate assessment, histology is needed, but this method is not viable for widespread clinical use.

MicroE...
For clinicians treating chronic diseases of the skin or prescribing therapies that modify skin structure, MicroElastic's Bullseye™ instantly quantifies skin thickness and elasticity. Unlike surface palpation, Bullseye ultrasonically probes the dermis for precise, robust and repeatable measurements, previously unattainable without biopsy. We believe that Bullseye will empower clinicians to identify and connect more patients with earlier interventions, select the right therapy at the right time, and optimize long-term treatment plans for lasting skin health.

Skin elasticity is driven by the amount of collagen in the dermis. As we age, collagen degrades, and skin loses elasticity and becomes saggy. Conversely, excess buildup of collagen in skin signifies damage or disease. Unfortunately, noninvasive methods of skin assessment via pinching/suction/compression are unreliable. For accurate assessment, histology is needed, but this method is not viable for widespread clinical use.

MicroElastic uses a proprietary type of elasticity measurement called Constructive Shear Wave Interference, optimized for use in portable, point-measurement systems without the complexity and cost of full-scale clinical imaging systems. The first implementation of this technology is a handheld ultrasound device that estimates skin elasticity at the touch of a button. It consists of a durable unit and sterile disposable caps that ensure soft and secure contact with the skin without liquid gel. The device will be simple to use, suitable for operation by any member of the clinical staff with minimal training. The device is protected by three patents licensed from Duke University. We have engaged with the FDA and are confident we will achieve 510(k) approval with identified predicates.

Graft-Versus-Host Disease (GVHD) provides a strategic beachhead application. An oft-deadly complication of stem cell transplant for the treatment of blood cancer, signs of onset or progression of GVHD (50% prevalence) must be carefully monitored throughout life. Stiffening skin is a primary biomarker of severity and predictor of outcome, but biopsy is too invasive for monitoring and the “pinch and score” standard is insufficient to track small changes (interrater agreement <30% overall, and <15% for intermediate stages). We believe that multidisciplinary blood cancer care teams can optimize management of and reduce the cost of treating patients at risk of cGVHD by $3000 per event thanks to Bullseye.
More information

Advisors

Bill Walker
Admin
Bill Walker Serial Medical Device Entrepreneur currently leading Entrepreneurship at Duke Engineering
Mark Palmeri
Admin
Mark Palmeri Associate Professor of the Practice of Biomedical Engineering

Employees

Kyle Langdell
Admin
Kyle Langdell CBO Head of marketing, strategy, and partnerships